Trastuzumab: A new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer

Future Oncology

Volumn 7, Issue 2, 2011, Pages 187-199

  Lordick, Florian ^a  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

advanced metastatic disease; biological agent; gastric cancer; HER2; monoclonal antibody; standard of care; trastuzumab

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; OXALIPLATIN; PERTUZUMAB; PF 299804; TRASTUZUMAB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROESOPHAGEAL JUNCTION CANCER; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79952161741     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.178     Document Type: Review

References (76)

1. Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J. Natl Compr. Canc. Netw. 8(4), 437-447 (2010).
2. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
3. Cunningham SC, Kamangar F, Kim MP et al.: Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J. Gastrointest. Surg. 9(5), 718-725 (2005).
4. Cunningham D, Starling N, Rao S et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008).
5. Kang YK, Kang WK, Shin DB et al.: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009).
6. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24(18), 2903-2909 (2006).
7. Van Cutsem E, Moiseyenko VM, Tjulandin S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24(31), 4991-4997 (2006).
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
10. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
11. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
12. Smith I, Procter M, Gelber RD et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29-36 (2007).
13. Koeppen HK, Wright BD, Burt AD et al.: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38(2), 96-104 (2001).
14. Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989).
15. Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9), 1523-1529 (2008). •• Review of the role of HER2 in gastric cancer.
16. Park DI, Yun JW, Park JH et al.: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 51(8), 1371-1379 (2006).
17. Hofmann M, Stoss O, Shi D et al.: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7), 797-805 (2008). • Initial guidance on scoring considerations for HER2 testing in gastric cancer.
18. Tanner M, Hollmen M, Junttila TT et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16(2), 273-278 (2005).
19. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W: HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell. Oncol. 32(1-2), 57-65 (2010).
20. Chung HC, Bang YJ, Xu JM et al.: Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing. Presented at: European Cancer Organisation 15/European Society for Medical Oncology 34. Berlin, Germany, 20-24 September 2009.
21. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50(5), 1550-1558 (1990).
22. Lewis GD, Figari I, Fendly B et al.: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37(4), 255-263 (1993).
23. Carter P, Presta L, Gorman CM et al.: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89(10), 4285-4289 (1992).
24. Cho HS, Mason K, Ramyar KX et al.: Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature 421(6924), 756-760 (2003).
25. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007). • Overview of trastuzumab activity and clinical potential.
26. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62(14), 4132-4141 (2002).
27. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61(12), 4744-4749 (2001).
28. Barok M, Isola J, Palyi-Krekk Z et al.: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6(7), 2065-2072 (2007).
29. Musolino A, Naldi N, Bortesi B et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789-1796 (2008).
30. Kim SY, Kim HP, Kim YJ et al.: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol. 32(1), 89-95 (2008).
31. Normanno N, Campiglio M, De LA et al.: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13(1), 65-72 (2002).
32. Pegram M, Hsu S, Lewis G et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18(13), 2241-2251 (1999).
33. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15(5), 537-547 (1997).
34. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol. 59(6), 795-805 (2007). • Preclinical findings indicating potential for chemotherapy plus trastuzumab in gastric cancer.
35. Tokuda Y, Ohnishi Y, Shimamura K et al.: In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br. J. Cancer 73(11), 1362-1365 (1996).
36. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int. J. Oncol. 27(3), 681-685 (2005).
37. + metastatic breast cancer. Cancer Chemother. Pharmacol. 56(4), 361-369 (2005).
38. Bang YJ, Van Cutsem E, Feyereislova A et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010). •• Key Phase III results from the Trastuzumab for Gastric Cancer (ToGA) study.
39. Cortes-Funes H, Rivera F, Ales I et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/ amplification. Presented at: 43rd American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
40. Nicholas G, Cripps C, Au H et al.: Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2. Presented at: 31st European Society for Medical Oncology Congress. Istanbul, Turkey, 29 September-3 October 2006.
41. Satoh T, Leon J, Lopez RI et al.: Quality of life results from a Phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. Presented at: 2010 Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22-24 January 2010.
42. Chung HC, Bang Y, Van Cutsem E et al.: (Q)-TWIST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. Presented at: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
43. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24(18), 2903-2909 (2006).
44. Al Batran SE, Hartmann JT, Probst S et al.: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26(9), 1435-1442 (2008).
45. Morris PG, Hudis CA: Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J. Clin. Oncol. 28(21), 3407-3410 (2010).
46. Rüschoff J, Nagelmeier I, Baretton G et al.: HER2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe 31(3), 208-217 (2010).
47. Geyer CE, Forster J, Lindquist D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
48. Hecht JR, Bang YJ, Sobrero A et al.: A Phase III study of CapeOx ± lapatinib in FISH-positive HER2 Locally advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. Presented at: European Cancer Organisation 15/ European Society for Medical Oncology 34. Berlin, Germany, 20-24 September 2009.
49. Satoh T, Bang Y, Wang J et al.: Interim safety analysis from TYTAN: a Phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. Presented at: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
50. Gonzales AJ, Hook KE, Althaus IW et al.: Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 7(7), 1880-1889 (2008).
51. Sergina NV, Rausch M, Wang D et al.: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126), 437-441 (2007).
52. Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009). •• Excellent review describing HER signaling and anti-HER therapies.
53. Hsieh AC, Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 97(4), 453-457 (2007).
54. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
55. Tzahar E, Waterman H, Chen X et al.: A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 16(10), 5276-5287 (1996).
56. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4), 317-328 (2004).
57. Hughes JB, Berger C, Rodland MS, Hasmann M, Stang E, Madshus IH: Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol. Cancer Ther. 8(7), 1885-1892 (2009).
58. Agus DB, Akita RW, Fox WD et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2), 127-137 (2002).
59. Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64(7), 2343-2346 (2004).
60. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69(24), 9330-9336 (2009).
61. Yamashita Y, Yorozu K, Kurasawa M, Fujimoto-Ouchi K: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers. Presented at: 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 17-21 April 2010.
62. Baselga J, Gelmon KA, Verma S et al.: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28(7), 1138-1144 (2010).
63. Junttila T, Fields C, Li G et al.: Trastuzumab-maytansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel. Presented at: EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'. Geneva, Switzerland, 21-24 October 2008.
64. Lewis Phillips GD, Li G, Dugger DL et al.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68(22), 9280-9290 (2008).
65. Parsons K, Crocker L, Leipold D et al.: Efficacy against HER2-positive trastuzumab-insensitive breast cancer models and enhanced response in trastuzumab-sensitive models. Presented at: American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 14-18 April 2007.
66. Krop I, LoRusso P, Miller D et al.: A Phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at: 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, USA, 10-13 December 2009.
67. + metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at: 35th European Society for Medical Oncology (ESMO) Congress. Milan, Italy, 8-12 October 2010.
68. Perez EA, Dirix L, Kocsis J et al.: Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label Phase 2 study. Presented at: 35th European Society for Medical Oncology (ESMO) Congress. Milan, Italy, 8-12 October 2010.
69. Rüschoff J, Dietel M, Baretton G et al.: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457(3), 299-307 (2010).
70. American Cancer Society: Global Cancer Facts and Figures 2007 www.cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf. pdf
71. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, USA http://seer.cancer.gov/csr/1975-2006
72. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer 2010 www.nccn.org/professionals/physician-gls/PDF/gastric.pdf
73. Herceptin® (trastuzumab). Summary of Product Characteristics. Roche Registration Ltd www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000278/WC500074922.pdf
74. Herceptin® (trastuzumab). Label information www.accessdata.fda.gov/ drugsatfda-docs/label/2010/103792s5250lbl.pdf
75. LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: a Phase III global, blinded study designed to evaluate clinical end points and saftey of chemothearpy plus lapatinib http://clinicaltrials.gov/ct2/ show/NCT00680901?term=logic&rank=5
76. PF-00299804 monotherapy in patients with HER2-positive advanced gastric cancer http://clinicaltrials.gov/ct2/show/NCT01152 853?term= PF+00299804&rank=1